148 related articles for article (PubMed ID: 31907296)
1. Recurrent chromosomal rearrangements of
Bayard Q; Caruso S; Couchy G; Rebouissou S; Bioulac Sage P; Balabaud C; Paradis V; Sturm N; de Muret A; Guettier C; Bonsang B; Copie C; Letouzé E; Calderaro J; Imbeaud S; Nault JC; Zucman-Rossi J
Gut; 2020 Sep; 69(9):1667-1676. PubMed ID: 31907296
[TBL] [Abstract][Full Text] [Related]
2. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.
Pilati C; Zucman-Rossi J
Cytokine Growth Factor Rev; 2015 Oct; 26(5):499-506. PubMed ID: 26188635
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.
Pilati C; Amessou M; Bihl MP; Balabaud C; Nhieu JT; Paradis V; Nault JC; Izard T; Bioulac-Sage P; Couchy G; Poussin K; Zucman-Rossi J
J Exp Med; 2011 Jul; 208(7):1359-66. PubMed ID: 21690253
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.
Pilati C; Letouzé E; Nault JC; Imbeaud S; Boulai A; Calderaro J; Poussin K; Franconi A; Couchy G; Morcrette G; Mallet M; Taouji S; Balabaud C; Terris B; Canal F; Paradis V; Scoazec JY; de Muret A; Guettier C; Bioulac-Sage P; Chevet E; Calvo F; Zucman-Rossi J
Cancer Cell; 2014 Apr; 25(4):428-41. PubMed ID: 24735922
[TBL] [Abstract][Full Text] [Related]
5. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
Nault JC; Couchy G; Balabaud C; Morcrette G; Caruso S; Blanc JF; Bacq Y; Calderaro J; Paradis V; Ramos J; Scoazec JY; Gnemmi V; Sturm N; Guettier C; Fabre M; Savier E; Chiche L; Labrune P; Selves J; Wendum D; Pilati C; Laurent A; De Muret A; Le Bail B; Rebouissou S; Imbeaud S; ; Bioulac-Sage P; Letouzé E; Zucman-Rossi J
Gastroenterology; 2017 Mar; 152(4):880-894.e6. PubMed ID: 27939373
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.
Poussin K; Pilati C; Couchy G; Calderaro J; Bioulac-Sage P; Bacq Y; Paradis V; Leteurtre E; Sturm N; Ramos J; Guettier C; Bardier-Dupas A; Boulai A; Wendum D; Selves J; Izard T; Nault JC; Zucman-Rossi J
Oncoimmunology; 2013 Dec; 2(12):e27090. PubMed ID: 24501689
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.
Calderaro J; Nault JC; Balabaud C; Couchy G; Saint-Paul MC; Azoulay D; Mehdaoui D; Luciani A; Zafrani ES; Bioulac-Sage P; Zucman-Rossi J
Mod Pathol; 2016 Jan; 29(1):43-50. PubMed ID: 26516697
[TBL] [Abstract][Full Text] [Related]
8. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.
Nault JC; Fabre M; Couchy G; Pilati C; Jeannot E; Tran Van Nhieu J; Saint-Paul MC; De Muret A; Redon MJ; Buffet C; Salenave S; Balabaud C; Prevot S; Labrune P; Bioulac-Sage P; Scoazec JY; Chanson P; Zucman-Rossi J
J Hepatol; 2012 Jan; 56(1):184-91. PubMed ID: 21835143
[TBL] [Abstract][Full Text] [Related]
9. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
Rebouissou S; Amessou M; Couchy G; Poussin K; Imbeaud S; Pilati C; Izard T; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
Nature; 2009 Jan; 457(7226):200-4. PubMed ID: 19020503
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.
Calderaro J; Labrune P; Morcrette G; Rebouissou S; Franco D; Prévot S; Quaglia A; Bedossa P; Libbrecht L; Terracciano L; Smit GP; Bioulac-Sage P; Zucman-Rossi J
J Hepatol; 2013 Feb; 58(2):350-7. PubMed ID: 23046672
[TBL] [Abstract][Full Text] [Related]
11. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
12. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
13. A novel type-1 cytokine receptor from fish involved in the Janus kinase/signal transducers and activators of transcription (Jak/STAT) signal pathway.
Santos MD; Yasuike M; Kondo H; Hirono I; Aoki T
Mol Immunol; 2007 Jul; 44(13):3355-63. PubMed ID: 17383728
[TBL] [Abstract][Full Text] [Related]
14. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
15. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434.
Pastuschek J; Poetzsch J; Morales-Prieto DM; Schleußner E; Markert UR; Georgiev G
J Reprod Immunol; 2015 Apr; 108():48-55. PubMed ID: 25817464
[TBL] [Abstract][Full Text] [Related]
17. Novel
Deland L; Keane S; Bontell TO; Fagman H; Sjögren H; Lind AE; Carén H; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Genomics Proteomics; 2022; 19(6):711-726. PubMed ID: 36316040
[TBL] [Abstract][Full Text] [Related]
18. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
19. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
20. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
